Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

依维莫司 医学 内科学 安慰剂 双盲 肾细胞癌 肿瘤科 泌尿科 病理 替代医学
作者
Robert J. Motzer,Bernard Escudier,Stéphane Oudard,Thomas E. Hutson,Camillo Porta,Sergio Bracarda,Viktor Grünwald,John A. Thompson,Robert A. Figlin,Norbert Hollaender,Gladys Urbanowitz,William J. Berg,Andrea Kay,David Lebwohl,Alain Ravaud
出处
期刊:The Lancet [Elsevier BV]
卷期号:372 (9637): 449-456 被引量:2951
标识
DOI:10.1016/s0140-6736(08)61039-9
摘要

Background Everolimus (RAD001) is an orally administered inhibitor of the mammalian target of rapamycin (mTOR), a therapeutic target for metastatic renal cell carcinoma. We did a phase III, randomised, double-blind, placebo-controlled trial of everolimus in patients with metastatic renal cell carcinoma whose disease had progressed on vascular endothelial growth factor-targeted therapy. Methods Patients with metastatic renal cell carcinoma which had progressed on sunitinib, sorafenib, or both, were randomly assigned in a two to one ratio to receive everolimus 10 mg once daily (n=272) or placebo (n=138), in conjunction with best supportive care. Randomisation was done centrally via an interactive voice response system using a validated computer system, and was stratified by Memorial Sloan-Kettering Cancer Center prognostic score and previous anticancer therapy, with a permuted block size of six. The primary endpoint was progression-free survival, assessed via a blinded, independent central review. The study was designed to be terminated after 290 events of progression. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00410124. Findings All randomised patients were included in efficacy analyses. The results of the second interim analysis indicated a significant difference in efficacy between arms and the trial was thus halted early after 191 progression events had been observed (101 [37%] events in the everolimus group, 90 [65%] in the placebo group; hazard ratio 0·30, 95% CI 0·22–0·40, p<0·0001; median progression-free survival 4·0 [95% CI 3·7–5·5] vs 1·9 [1·8–1·9] months). Stomatitis (107 [40%] patients in the everolimus group vs 11 [8%] in the placebo group), rash (66 [25%] vs six [4%]), and fatigue (53 [20%] vs 22 [16%]) were the most commonly reported adverse events, but were mostly mild or moderate in severity. Pneumonitis (any grade) was detected in 22 (8%) patients in the everolimus group, of whom eight had pneumonitis of grade 3 severity. Interpretation Treatment with everolimus prolongs progression-free survival relative to placebo in patients with metastatic renal cell carcinoma that had progressed on other targeted therapies. Funding Novartis Oncology.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
zycdx3906发布了新的文献求助10
刚刚
1秒前
melon完成签到,获得积分10
1秒前
1秒前
1秒前
明眸发布了新的文献求助10
1秒前
2秒前
2秒前
3秒前
4秒前
5秒前
舒服的寻云完成签到 ,获得积分10
5秒前
心情发布了新的文献求助10
5秒前
baolequ发布了新的文献求助10
6秒前
6秒前
安然完成签到,获得积分10
6秒前
miaoww完成签到,获得积分10
6秒前
鑫搭发布了新的文献求助10
6秒前
6秒前
白紫寒完成签到 ,获得积分10
7秒前
陌路孤星发布了新的文献求助10
7秒前
7秒前
qaa2274278941发布了新的文献求助10
8秒前
豪士赋完成签到,获得积分10
8秒前
hume发布了新的文献求助10
8秒前
好远加身完成签到,获得积分10
8秒前
9秒前
9秒前
大个应助结实红酒采纳,获得10
10秒前
11秒前
bkagyin应助科学宇宙采纳,获得10
11秒前
课呢发布了新的文献求助10
11秒前
科研通AI2S应助你没事吧采纳,获得10
11秒前
毛毛发布了新的文献求助10
12秒前
baolequ完成签到,获得积分10
12秒前
Owen应助qxy采纳,获得10
12秒前
13秒前
CodeCraft应助qaa2274278941采纳,获得10
13秒前
万能图书馆应助Volta_zz采纳,获得10
14秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974358
求助须知:如何正确求助?哪些是违规求助? 3518706
关于积分的说明 11195521
捐赠科研通 3254897
什么是DOI,文献DOI怎么找? 1797614
邀请新用户注册赠送积分活动 877011
科研通“疑难数据库(出版商)”最低求助积分说明 806128